New York Weil Cornell University ONC 525 E 68Th St, New York, NY 10065 212-746-2060 (Phone)
Certifications:
Hematology, 1988 Internal Medicine, 1985 Medical Oncology, 1989
Awards:
Healthgrades Honor Roll
Languages:
English
Hospitals:
New York Weil Cornell University ONC 525 E 68Th St, New York, NY 10065
NewYork-Presbyterian/Weill Cornell Medical Center 525 East 68Th Street, New York, NY 10065
Education:
Medical School Washington University St Louis Graduated: 1982 Medical School New York Hospital Graduated: 1983 Medical School New York Hospital Graduated: 1985
Barbara L. Hempstead - New York NY, US Rosemary Kraemer - Brooklyn NY, US Shahin Rafii - Great Neck NY, US Phi Wiegn - New York NY, US Michael L. Donovan - Brookline MA, US
Assignee:
Cornell Research Foundation, Inc. - Ithaca NY Children's Medical Center Corporation - Boston MA
International Classification:
A61K 38/18
US Classification:
514 2, 514 12, 530399
Abstract:
The present invention relates to methods of inducing or inhibiting the angiogenic process and promoting vessel growth or stabilization in an organ by modulating the trk receptor pathway. The present invention also relates to a method for treating a pathological disorder in a patient which includes administering a trk receptor ligand or an inhibitor or expression or activity of a trk receptor ligand. The present invention also relates to a method of screening for a modulator of angiogenesis, vessel growth, or vessel stabilization. Another aspect of the present invention is a method of diagnosing or monitoring a pathological disorder in a patient which includes determining the presence or amount of a trk receptor ligand or activation of a trk receptor ligand in a biological sample.
Jay M. Edelberg - New York NY, US Dong Qing Cai - Guangzhou, CN Barbara L. Hempstead - New York NY, US
Assignee:
Cornell Research Foundation, Inc. - Ithaca NY
International Classification:
A61K 38/04 A61K 38/00 A61K 51/00
US Classification:
530329, 530300, 530324, 514 11, 424 169
Abstract:
The present invention relates to peptides which selectively or preferentially home to areas of a heart. The invention further relates to conjugates of the homing peptides and uses thereof.
Method For Inhibiting Apoptosis Through The P75 Neurotrophin Receptor
Barbara L. Hempstead - New York NY, US Ramee Lee - New York NY, US Kenneth K. Teng - New York NY, US Pouneh Kermani - Great Neck NY, US
Assignee:
Cornell Research Foundation, Inc. - Ithaca NY
International Classification:
A61K 39/395
US Classification:
4241581
Abstract:
The present invention provides an isolated protein comprising a pro-domain of a proneurotrophin, methods for producing the protein, and pharmaceutical compositions containing the isolated protein. The invention also provides a nucleic acid molecule which encodes the protein and a vector containing the nucleic acid molecule. The present invention further provides a method for cleaving a proneurotrophin protein to a mature neurotrophin. In addition, the invention relates to methods for inducing apoptosis in a cell of a mammal expressing p75 surface receptors or p75 and trk receptors. The methods include causing the p75 receptor to bind a pharmaceutical composition containing a pro-domain of a proneurotrophin or administering to the mammal an effective amount of a cleavage-resistant proneurotrophin and an inhibitor of trk activation. The invention also relates to a method for inhibiting apoptosis of a cell in a mammal by administering an effective amount of a molecule which inhibits binding of a proneurotrophin to a p75 receptor. Also provided, are kits and methods for screening a human for a condition associated with undesired apoptosis.
High Affinity Ligand For P75 Neurotrophin Receptor
The present invention provides an isolated protein comprising a pro-domain of a proneurotrophin, methods for producing the protein, and pharmaceutical compositions containing the isolated protein. The invention also provides a nucleic acid molecule which encodes the protein and a vector containing the nucleic acid molecule. The present invention further provides a method for cleaving a proneurotrophin protein to a mature neurotrophin. In addition, the invention relates to methods for inducing apoptosis in a cell of a mammal expressing p75 surface receptors or p75 and trk receptors. The methods include causing the p75 receptor to bind a pharmaceutical composition containing a pro-domain of a proneurotrophin or administering to the mammal an effective amount of a cleavage-resistant proneurotrophin and an inhibitor of trk activation. The invention also relates to a method for inhibiting apoptosis of a cell in a mammal by administering an effective amount of a molecule which inhibits binding of a proneurotrophin to a p75 receptor. Also provided, are kits and methods for screening a human for a condition associated with undesired apoptosis.
Methods For Regulating Angiogenesis And Vascular Integrity Using Trk Receptor Ligands
Barbara L. HEMPSTEAD - New York NY, US Rosemary KRAEMER - Brooklyn NY, US Shahin RAFII - Great Neck NY, US Phi WIEGN - New York NY, US Michael J. DONOVAN - Brookline MA, US
Assignee:
CORNELL RESEARCH FOUNDATION, INC. - Ithaca NY CHILDREN'S MEDICAL CENTER CORPORATION - Boston MA
International Classification:
A61K 38/12 A61P 7/00
US Classification:
514 12
Abstract:
The present invention relates to methods of inducing or inhibiting the angiogenic process and promoting vessel growth or stabilization in an organ by modulating the trk receptor pathway. The present invention also relates to a method for treating a pathological disorder in a patient which includes administering a trk receptor ligand or an inhibitor or expression or activity of a trk receptor ligand. The present invention also relates to a method of screening for a modulator of angiogenesis, vessel growth, or vessel stabilization. Another aspect of the present invention is a method of diagnosing or monitoring a pathological disorder in a patient which includes determining the presence or amount of a trk receptor ligand or activation of a trk receptor ligand in a biological sample.
Method To Determine And Biomarker For Treatment Efficacy With Ssri, Snri, And Sari Antidepressants
Francis S. Lee - New York NY, US Barbara L. Hempstead - New York NY, US Kevin G. Bath - New York NY, US
International Classification:
C12Q 1/68 A61K 31/138 A61P 25/24
US Classification:
514651, 435 6
Abstract:
The invention provides a method for determining whether a patient suffering from a condition that is susceptible to treatment with a compound that activates the brain serotonin system is resistant to treatment with the compound. The method comprises observing whether the genome of the patient contains at least one copy of the BDNF allele containing a genetic alteration, and correlating the presence of the allele containing the genetic alteration with patients who are resistant to treatment with the compound. In another embodiment, the method comprises observing whether the patient expresses a BDNF protein containing an amino acid alteration, and correlating the expression of the BDNF protein containing the amino acid alteration with patients who are resistant to treatment with the compound.
The present invention relates to a method of inhibiting cellular uptake of pro-nerve growth factor (proNGF) in a cell expressing neurotrophin p75 receptor in a mammal in need thereof. Such mammals include, for example, those suffering from neuropathological conditions. In another aspect, the invention relates to a method of promoting cellular uptake of proNGF in a cell expressing p75receptor in a mammal in need thereof. Such mammals include, for example, those suffering from conditions relating to human and other mammalian hair follicle cycling.
Method For Determining Sensitivity Or Resistance To Compounds That Activate The Brain Serotonin System
Francis S. Lee - New York NY, US Barbara Hempstead - New York NY, US James Kocsis - Roxbury CT, US Kevin Bath - New York NY, US
Assignee:
CORNELL UNIVERSITY - Ithaca NY
International Classification:
A61K 31/135 C12Q 1/68 A61P 25/24
US Classification:
514651, 435 613, 435 611
Abstract:
The invention relates to a method for determining whether a patient suffering from a condition that is susceptible to treatment with a compound that activates the brain serotonin system is susceptible or resistant to treatment with the compound. The method includes establishing whether the patient is a pre-adult, a transition age patient, or an adult and observing whether the genome of the patient contains at least one copy of a BDNF allele having a genetic alteration. The method further includes correlating the presence of the allele containing the genetic alteration with susceptibility or resistance of the patient to the treatment with the compound, wherein a pre-adult patient containing the genetic alteration is correlated as being susceptible to the treatment; a transition age patient containing the genetic alteration is correlated as being susceptible or resistant to the treatment; and an adult patient containing the genetic alteration is correlated as being resistant to the treatment.
The phenomenon has been established over the course of, easily, the last decade, said neuroscientist Barbara Hempstead of Weill Cornell Medical College in New York, who was not involved in the new work. It's just, we didn't understand the mechanism.